SXTP on Nasdaq

60 DEGREES PHARMACEUTICALS, INC.

American pharmaceutical preparations company based in Washington. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Galena Biopharma, Kitov Pharma or Shattuck Labs, Inc., or pick any stock.

  • TickerSXTP on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWashington, the District of Columbia1
  • Incorporated inDE2
  • Business address1025 Connecticut Avenue Nw, Suite 1000, Washington, Dc 200362
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

22.3%Gross margin3
-771.6%Operating margin3
-732.5%Net margin3
65.5%Revenue growth, 20253
-212.7%Return on equity3
0.04×Debt to equity3
-$7.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue27¢$781.7K
  • Research and development73¢$2.1M

Out of $1.0M in revenue.3 The company lost money this year.

Financial statements

Revenue453$1.0M in 2025+350% since 2022
0$500.0K$1.0M$1.5M2022: $223.2K$223.2K20222023: $253.6K$253.6K2023+14%2024: $607.6K$607.6K2024+140%2025: $1.0M$1.0M2025+65%
Gross profit453$223.8K in 2025
-$400.0K-$200.0K0$200.0K$400.0K2022: -$209.2K-$209.2K20222023: -$221.0K-$221.0K2023+6%2024: $222.8K$222.8K20242025: $223.8K$223.8K2025+0%
Operating income453-$7.8M in 2025+343% since 2022
-$10.0M-$7.5M-$5.0M-$2.5M02022: -$1.8M-$1.8M20222023: -$5.2M-$5.2M2023+194%2024: -$9.7M-$9.7M2024+88%2025: -$7.8M-$7.8M2025−20%
Net income453-$7.4M in 2025+19% since 2022
-$8.0M-$6.0M-$4.0M-$2.0M02022: -$6.2M-$6.2M20222023: -$3.8M-$3.8M2023−39%2024: -$7.9M-$7.9M2024+111%2025: -$7.4M-$7.4M2025−7%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Product Revenues net of Discounts and Rebates$1.0M$607.6K
Cost of Revenues$781.7K$384.8K
Gross Profit$223.8K$222.8K
Research Revenues$403.6K$73.8K
Net Revenue$627.4K$296.6K
Research and Development$2.1M$5.0M
General and Administrative Expenses$6.3M$5.0M
Total Operating Expenses$8.4M$10.0M
Loss from Operations-$7.8M-$9.7M
Interest Expense-$7.8K-$7.9K
Change in Fair Value of Derivative Liabilities$266.1K$1.7M
Other Income, net$132.0K$101.5K
Total Interest and Other Income (Expense), net$390.3K$1.8M
Loss from Operations before Provision for Income Taxes-$7.4M-$8.0M
Provision for Income Taxes (Note 9)$0$0
Net Loss Noncontrolling Interest-$3.2K-$8.6K
Net Loss attributed to 60 Degrees Pharmaceuticals, Inc.-$7.4M-$7.9M
Net Loss-$7.4M-$8.0M
Unrealized Foreign Currency Translation Gain (Loss)$7.1K-$90
Total Comprehensive Loss-$7.4M-$8.0M
Net Loss Noncontrolling Interest-$3.2K-$8.6K
Comprehensive Loss attributed to 60 Degrees Pharmaceuticals, Inc.-$7.4M-$7.9M
Cumulative Dividends on Series A Preferred Stock-$501.1K-$483.3K
Net Loss - attributed to common stockholders-$7.9M-$8.4M
Basic (in Dollars per share)-$11.73-$74.17
Diluted (in Dollars per share)-$11.73-$74.17
Basic (in Shares)670.2K shares113.7K shares
Diluted (in Shares)670.2K shares113.7K shares

Compare 60 DEGREES PHARMACEUTICALS, INC. with another company

Leadership

Who has led 60 DEGREES PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Geoffrey S. Dow2023–now

President

  1. Geoffrey S. Dow2023–now

Chief financial officer

  1. Tyrone Miller2023–2025

Chief operating officer

  1. Kristen Landon2025–now
2025
Board members and other officers (6)

Timeline

  1. Jul 11, 2023New chief executive Geoffrey S. Dow becomes CEO8

Filings

220 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 47 major events, 40 insider forms, 21 large holders, 3 private raises, 96 other. The latest 20:

  1. Oct 6, 20268-K CURRENT REPORT EDGAR
  2. Sep 14, 20268-K CURRENT REPORT EDGAR
  3. Sep 8, 20268-K CURRENT REPORT EDGAR
  4. Aug 25, 2026EFFECT EDGAR
  5. Aug 17, 2026DEL AM DELAYING AMENDMENT EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Aug 14, 2026S-3 REGISTRATION STATEMENT EDGAR
  8. Aug 6, 20268-K CURRENT REPORT EDGAR
  9. Aug 5, 2026SCHEDULE 13G EDGAR
  10. Aug 4, 20268-K CURRENT REPORT EDGAR
  11. Jul 29, 20263 EDGAR
  12. Jul 29, 2026SCHEDULE 13G EDGAR
  13. Jul 20, 20268-K CURRENT REPORT EDGAR
  14. Jul 9, 20268-K CURRENT REPORT EDGAR
  15. Jul 2, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  16. Jun 15, 20264 EDGAR
  17. Jun 8, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  18. Jun 3, 20268-K CURRENT REPORT EDGAR
  19. May 19, 20263 EDGAR
  20. May 18, 20268-K CURRENT REPORT EDGAR

The 220 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

17 open-market trades by officers, directors and large owners since October 2021: 17 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 12, 2026DOW GEOFFREY SPresident and CEOBuy7,350$1.38$10.1KForm 4
Dec 15, 2025DOW GEOFFREY SPresident and CEOBuy9,670$0.80$7.7KForm 4
Dec 11, 2025DOW GEOFFREY SPresident and CEOBuy3,613$0.92$3.3KForm 4
Dec 10, 2025DOW GEOFFREY SPresident and CEOBuy9,350$0.95$8.9KForm 4
Jun 3, 2025XU CHERYLDirectorBuy5,000$2.88$14.4KForm 4
Dec 16, 2024XU CHERYLDirectorBuy2,000$1.45$2.9KForm 4
Dec 13, 2024XU CHERYLDirectorBuy6,000$1.56$9.4KForm 4
Dec 12, 2024XU CHERYLDirectorBuy5,000$1.82$9.1KForm 4
Dec 9, 2024DOW GEOFFREY SPresident and CEOBuy35,823$1.27$45.5KForm 4
Dec 6, 2024DOW GEOFFREY SPresident and CEOBuy20,579$1.20$24.7KForm 4
Dec 5, 2024DOW GEOFFREY SPresident and CEOBuy17,549$1.11$19.5KForm 4
Nov 21, 2024DOW GEOFFREY SPresident and CEOBuy3,500$0.91$3.2KForm 4
Nov 20, 2024DOW GEOFFREY SPresident and CEOBuy1,000$0.92$920Form 4
Nov 19, 2024DOW GEOFFREY SPresident and CEOBuy2,500$0.90$2.2KForm 4
Aug 27, 2024XU CHERYLDirectorBuy5,000$1.70$8.5KForm 4
Jan 31, 2024DOW GEOFFREY SPresident and CEOBuy25,974$0.38$9.9KForm 4
Jan 31, 2024XU CHERYLDirectorBuy200,000$0.38$76.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 5, 2025Raised $1.1 million in a private offering of securities Form D: 4 investors so far Form D
  2. Jan 28, 2025Raised $1 million in a private offering of securities Form D: 4 investors so far Form D
  3. May 19, 2022Raised $1.8 million in a private offering of securities Form D: 10 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kathmere Capital Management, LLC265,100$466.6K0.0%+120,417
Citadel Advisors LLC22,362$39.4K0.0%New
XTX Topco Ltd17,639$31.0K0.0%New
Kovack Advisors, Inc.15,000$26.4K0.0%New
Geode Capital Management, LLC14,551$25.6K0.0%−1,744
UBS Group AG13,592$23.9K0.0%−17,818
Barclays PLC1,052$1.9K0.0%−804
Osaic Holdings, Inc.25$440.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23